Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar pokerden (< 20) Submitted: 3/15/2007 4:22:24 PM : Outperform Start Price: $2.68 HALO Score: +206.09

Tons of potential and partnerships already with roche and baxter. Look for more partnerships and revenue to start flowing in...now alot of downside on this stock for the new future.

Featured Broker Partners


Advertisement